JPRN-jRCT2080222711未知2 期
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of SPI-8811 Oral Solution in Patients With Non-erosive Reflux Disease (NERD) Refractory to Proton Pump Inhibitors
Sucampo Pharma, LLC.0 个研究点开始时间: 2014年12月26日最近更新:
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 70age old（—）
- 性别
- All
入选标准
- •Patient has non-erosive reflux disease and insufficient response to the standard dose of a PPI.
- •Patient who has no mucosal change by upper gastrointestinal tract endoscopy on the day before the study treatment.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar PsoriasisEUCTR2012-005412-25-NLovartis Pharma Services AG201
进行中（未招募）
1 期
Rapastinel Versus placebo to prevent relapse of Major depressioMajor depressive disorderMedDRA version: 20.0Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2018-000064-28-SEAllergan Ltd.1,400
进行中（未招募）
1 期
Hidradenitis Suppurativa Phase 3 Study of IzokibepMedDRA version: 20.0Level: LLTClassification code: 10020041Term: Hidradenitis suppurativa Class: 10040785Hidradenitis SuppurativaCTIS2022-503160-33-00Acelyrin Inc.250
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate theSafety, Tolerability, and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis and an Inadequate Response to MethotrexateRheumatoid arthritis (RA)MedDRA version: 12.0Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2009-012566-32-PLAmgen Inc240
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive MedicatioHypertensionEUCTR2021-003776-13-LTAlnylam Pharmaceuticals, Inc.1,800